In addition, PI3K inhibitors and BEZ235 (dual PI3K/mTOR inhibitor) suppress trastuzumab-resistant breast cancer cell proliferation by inhibiting the PI3K/AKT/mTOR pathway (Kataoka et al., 2010; O’Brien et al., 2014). Here, PIK3CB is linked to breast carcinoma.